Full year update on Pixium Vision's liquidity agreement with Gilbert Dupont
Paris, January 3, 2019 - 07:00 AM CET - Under the liquidity agreement signed between Pixium Vision and Société de Bourse Gilbert Dupont, the following resources were listed in the liquidity account on December 31, 2018:
- 36,217 Pixium Vision shares
- € 95,846.99
It is specified that as of June 30, 2018, the following resources were listed in the liquidity account:
- 43,247 Pixium Vision shares
- € 74,504.57
Contacts
| Pixium Vision Didier Laurens, CFO investors@pixium-vision.com +33 1 76 21 47 68 | Media Relations Newcap Media Annie-Florence Loyer - afloyer@newcap.fr +33 1 44 71 00 12 / +33 6 88 20 35 59 Léa Jacquin - ljacquin@newcap.fr +33 1 44 71 94 94 | US Investor Relations ICR David Clair david.clair@icrinc.com +1 646 277 12 66 |
ABOUT PIXIUM VISION
Pixium Vision's mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy. Pixium Vision's bionic vision systems are associated with a surgical intervention and a rehabilitation period. Pixium Vision is in clinical stage with PRIMA, its sub-retinal miniature photovoltaic wireless implant system, designed for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners spanning across the prestigious Vision research institutions including Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, and Institute of Ocular Microsurgery (IMO) in Barcelona. The company is EN ISO 13485 certified and qualifies as "Entreprise Innovante" by Bpifrance.
For more information, please visit: www.pixium-vision.com ; And follow us on: @PixiumVision; www.facebook.com/pixiumvision www.linkedin.com/company/pixium-vision
Disclaimer:
This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward looking statements.
Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise. For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company's Registration Document filed with the AMF under number R16-033 on April 28, 2016 which can be found on the websites of the AMF - AMF ( www.amf-france.org ) and of Pixium Vision ( www.pixium-vision.com ).
IRIS ® is trademark of Pixium-Vision SA
Attachment
